Hutchmed (00013) Rises Over 4% Again, Up More Than 20% This Month; SACHI Phase III Study Results Published in The Lancet

Stock News01-16

HUTCHMED (00013) rose more than 4% again, bringing its cumulative gain for the month to over 20%. At the time of writing, the stock was up 3.68% to HK$24.8, with a turnover of HK$142 million.

The company announced that the results from the SACHI Phase III study have been published in The Lancet. SACHI is a Phase III study evaluating the combination therapy of savolitinib and osimertinib for the treatment of patients with EGFR mutation-positive locally advanced or metastatic non-small cell lung cancer who have experienced disease progression after first-line EGFR tyrosine kinase inhibitor therapy and have MET amplification.

Savolitinib is a potent, highly selective oral MET TKI, co-developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. Osimertinib is an irreversible, third-generation EGFR TKI.

Based on the data from the SACHI study, the combination therapy of savolitinib and osimertinib was approved in China in June 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment